Business
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 19, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.\n \n \n \n \n \n \n \nAlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for Alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.\"We know from conversations with the Alpha-1 community that AATD (Alpha-1 Antitrypsin Deficiency) is highly underdiagnosed and often misdiagnosed. We're proud to support AlphaDetect as an inaugural sponsor and especially excited about this centralized lab for Alpha-1 testing and detection, supported by a team dedicated to the Alpha-1 community,\" said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. \"In addition to genetic testing, AlphaDetect is part of a broader effort to connect people living with Alpha-1 to care, resources, and ongoing research that may potentially have a significant impact on their quality of life and the progression of their disease.\"\"Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences,\" said Julie Murray, CEO of AlphaDetect. \"The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Wave Life Sciences are important and appreciated as we continue to advance Alpha-1 detec...